Drug
Amrubicin clinical trials
Also written Calsed and SM-5887.
- studies test it
- 17
- open now
- 1
- in phase 3
- 4
- first study started
- 2004
Keep track of what changes. Save the amrubicin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2006 (4)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 4 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 4 |
| 2011 | 4 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 10
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 8
Celgene (4) · SCRI Development Innovations, LLC (2) · Celgene Corporation (2) · Heather Wakelee (1) · Michaela Liedtke (1) · University of Utah (1) · Lawrence Einhorn (1) · Sumitomo Pharma (Suzhou) Co., Ltd. (1)
Often tested with
Tested in the same studies.
Cisplatin (1) · Lenalidomide (1) · Dexamethasone (1) · Carboplatin (1) · Pegfilgrastim (1) · Cyclophosphamide (1) · Irinotecan (1) · Sacituzumab govitecan (1)
Studies
Open first, then newest update. How each study uses amrubicin is read from its arms, and is right about nine times in ten.
Testing it · 17
- Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerRecruitingPhase 3Gilead SciencesNCT06801834Written as Amrubicin (Japan only)
- Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast CancerCompletedPhase 1/2SCRI Development Innovations, LLCNCT01033032Written as Amrubicin
- Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)TerminatedPhase 3Sumitomo Pharma Co., Ltd.NCT00286169Written as Amrubicin Hydrochloride
- Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung CancerCompletedPhase 2CelgeneNCT00388960Written as Amrubicin
- AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line ChemotherapyCompletedPhase 3CelgeneNCT00547651Written as Amrubicin
- A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.CompletedPhase 1CelgeneNCT00915083Written as Amrubicin
- Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior TherapyCompletedPhase 2CelgeneNCT00375193Written as Amrubicin
- A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic MalignanciesCompletedPhase 2Heather WakeleeNCT01364727Written as Amrubicin
- Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedPhase 1/2Michaela LiedtkeNCT01355705Written as Amrubicin
- Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial CarcinomaTerminatedPhase 2Matthew GalskyNCT01331824Written as Amrubicin
- Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue SarcomaCompletedPhase 2University of UtahNCT01259375Written as Amrubicin
- A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung CancerCompletedPhase 2SCRI Development Innovations, LLCNCT01076504Written as Amrubicin
- Amrubicin + Cyclophosphamide in Advanced Solid Organ MalignanciesCompletedPhase 1Lawrence EinhornNCT00890955Written as Amrubicin
- Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung CancerCompletedPhase 3Sumitomo Pharma (Suzhou) Co., Ltd.NCT00660504Written as Amrubicin Hydrochloride
- Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung CancerCompletedPhase 1Japan Multinational Trial OrganizationNCT00132054Written as amrubicin hydrochloride
- Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.CompletedPhase 2Celgene CorporationNCT00319969Written as Amrubicin
- Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast CancerWithdrawnPhase 2Celgene CorporationNCT00380835Written as Amrubicin
As the comparator · 5 — what is tested is compared with amrubicin
- A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerRecruitingPhase 3AbbVieNCT07365241Written as Amrubicin
- A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerRecruitingPhase 3Daiichi SankyoNCT06203210Written as Amrubicin
- Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerActive, not recruitingPhase 3AmgenNCT05740566Written as Amrubicin
- A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based ChemotherapyTerminatedPhase 2Taiho Oncology, Inc.NCT01904253Written as Amrubicin (Japan)
- Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerCompletedPhase 3Bristol-Myers SquibbNCT02481830Written as Amrubicin
Codes
What other systems call amrubicin · ClinicalTrials.gg INT003376
- MeSH (NLM) C055866amrubicinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 93N13LB4Z2AMRUBICINConfirmed FDA, NLM, Wikidata
- Wikidata Q4748723amrubicinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C80089AmrubicinOne source FDA
- DrugBank DB06263One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C055866 | amrubicin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 93N13LB4Z2 | AMRUBICIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4748723 | amrubicin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C80089 | Amrubicin | One source FDA |
| DrugBank | DB06263 | — | One source Wikidata |
Also registered as amrubicin hydrochloride (UNII EUL6MP8FZW).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.